Companies › Innovent Biologics Technology Limited (Shanghai R&D Center)
3 active drug programs in 4 registered trials: 2 Phase 2, 1 Phase 1, 1 Phase 3; Metabolic and endocrine, Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tigulixostat (IBI128) Xanthine dehydrogenase inhibitor | XDH | Phase 3 | Gout | Apr 2027 |
| IBI302 | – | Phase 2 | Neovascular Age-related Macular Degeneration; Diabetic Macular Oedema | Dec 2026 |
| IBI3032 GLP-1 receptor agonist | – | Phase 1 | Overweight or Obesity | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07170319 | IBI3032 | Phase 1 | Overweight or Obesity | Metabolic and endocrine | Dec 2025 |
| NCT07275840 | IBI302 | Phase 2 | Neovascular Age-related Macular Degeneration | Ophthalmology | Aug 2026 |
| NCT06908876 | IBI302 | Phase 2 | Diabetic Macular Oedema | Ophthalmology | Dec 2026 |
| NCT07414394 | Tigulixostat (IBI128) | Phase 3 | Gout | Metabolic and endocrine | Apr 2027 |
Arthrosi Therapeutics Shenyang Sunshine Pharmaceutical Shanghai Institute Of Biological Products
Ascletis Pharma (China) The United Bio-Technology (Hengqin) JCR Pharmaceuticals Beijing QL Biopharmaceutical Gan & Lee Pharmaceuticals.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.